Meet the team
Medication Safety Officer (MSO) – Cardiff and Vale UHB Hi, I’ve been asked to share with you my experience in the role of Medication Safety Officer (MSO) – a part of my job I...
Medication Safety Officer (MSO) – Cardiff and Vale UHB Hi, I’ve been asked to share with you my experience in the role of Medication Safety Officer (MSO) – a part of my job I...
To aid in the appropriate use of medicines during the current Coronavirus (COVID-19) pandemic, AWTTC have provided therapeutic advice for information on the AWTTC.org website.
Did you know that The Welsh Medicines Information Centre now offer an e-Advice service? This service can be accessed using the current e-Advice platform produced and provided by Cardiff and Vale University Health Board:...
There is an update to the Porphyria Q&A for What is the most suitable treatment for acne in a patient with acute porphyria?
There is an update to the Complementary medicine Q&A for ‘Considerations when addressing questions about potential for adverse effects and drug interactions with homeopathic remedies‘.
There is an update to the UKMi Medicines Q&A for ‘What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs)?‘
There is an update to the Porphyria Q&A for ‘What advice should be given to patients with porphyria who intend to travel?‘
This UKMi Q&A covers the management of crusted scabies and of classical scabies that is difficult to treat.
CV42 methylphenidate for attention deficit hyperactivity disorder (ADHD), hyperkinetic disorder (HKD). Access to Shared care supporting documents and list of additional Shared Care Protocols
CV46 atomoxetine for attention deficit hyperactivity disorder (ADHD), hyperkinetic disorder (HKD) in children 6 years and older, adolescents and adults. Access to Shared care supporting documents and list of additional Shared Care Protocols